Search clinical trials for: HIV-1 GW873140 CCR5 antagonist experienced

Total 81674 results

GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

United States, Belgium
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
GlaxoSmithKline

Terminated

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

Germany
GlaxoSmithKline

Terminated

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus

HIV Infection

United States
ViiV Healthcare
Pfizer

Completed

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

CCR5-tropic HIV-1 Infection
National Institute of Allergy and Infectious Diseases...

Completed

GW873140 to Treat HIV-1 Infected Adults

HIV Infections

United States
University of Maryland, Baltimore

Withdrawn

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

Hiv | Kidney Transplant | HIV Reservoir | CCR5

United States
National Institute of Allergy and Infectious Diseases...

Completed

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

HIV Infections | Kidney Diseases

United States
Tobira Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

HIV-1 Infection

United States, Puerto Rico
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Fundacion para la Investigacion Biomedica del Hospital...

Terminated

Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication (CHEMOMAR)

HIV-1 Infection

Spain
Incyte Corporation

Completed

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

HIV Infections

United States
ViiV Healthcare
Pfizer

No longer available

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

HIV

Canada
University of California, San Francisco
Pfizer; ViiV Healthcare

Completed

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Kaposi's Sarcoma

United States
Fundacion para la Investigacion Biomedica del Hospital...
Pfizer

Completed

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

HIV-1

Spain
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Germans Trias i Pujol Hospital

Completed

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

HIV Infections

Spain
Cepheid

Completed

Clinical Evaluation of the Xpert® HIV-1 VL

Human Immunodeficiency Virus
Wellness Wheel Medical Clinic
University of Saskatchewan; Saskatchewan Health Authority - Regina Area; CIHR...

Recruiting

Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan (SHIVER)

HIV Infections | Syphilis

Canada
Sangamo Therapeutics

Terminated

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

HIV-1-infection

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

HIV Infections

United States
ViiV Healthcare

Terminated

GW873140 In Combination With Kaletra In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Germany, France, Canada, Spain, Italy, Portugal, United Kingdom, Denmark, Netherlands
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

HIV Infection

United States
National Institutes of Health Clinical Center (CC)

Completed

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

HIV Infection | Hepatitis C

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

HIV-1-infection

Uganda
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
GlaxoSmithKline

Terminated

GSK706769 A First Time in Human Study For Males and Females

Healthy Subjects

United States
MRC/UVRI and LSHTM Uganda Research Unit
Karolinska Institutet; Amsterdam Institute for Global Health and Development; University of Rwanda and other collaborators

Recruiting

East Africa Point of Care Viral Load Study (EAPoC-VL)

HIV | Viral Load | Point of Care Monitoring

Kenya, Uganda
Tobira Therapeutics, Inc.

Completed

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

HIV

Spain
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
University of Washington
University of Nairobi

Completed

Patient Actor Training to Improve HIV Services for Adolescents in Kenya (SPEED)

HIV/AIDS

Kenya
Merck Sharp & Dohme LLC

Terminated

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

HIV Infections
Johns Hopkins University
Centers for Disease Control and Prevention

Recruiting

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) (EHPOC)

HIV Infections | Syphilis

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Janssen-Cilag Ltd.

Completed

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

HIV-1

Taiwan
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
University of Cincinnati
University of California, San Francisco; Case Western Reserve University

Completed

CCR5-modified CD4+ T Cells for HIV Infection (TRAILBLAZER)

HIV Infections

United States
CytoDyn, Inc.
Amarex Clinical Research

No longer available

An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (CD02_EA)

HIV

United States
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
City of Hope Medical Center
Sangamo Therapeutics; California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

HIV

United States
Pfizer

Terminated

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

HIV-1

Spain, United Kingdom, Malaysia, United States, Portugal, Brazil, Germany, Italy, Poland, Puerto Rico, South Africa, Taiwan, Ukraine
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
Viriom

Completed

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

HIV-1-infection

Russian Federation

Search clinical trials for: HIV-1 GW873140 CCR5 antagonist experienced

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations